Cargando…

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

BACKGROUND: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma. PATIENTS AND METHODS: From May 2010 to May 2011, 10 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartrampf, Philipp E., Hänscheid, Heribert, Kertels, Olivia, Schirbel, Andreas, Kreissl, Michael C., Flentje, Michael, Sweeney, Reinhart A., Buck, Andreas K., Polat, Bülent, Lapa, Constantin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075763/ https://www.ncbi.nlm.nih.gov/pubmed/32195377 http://dx.doi.org/10.1016/j.ctro.2020.03.002

Ejemplares similares

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
por: Kreissl, Michael C, et al.
Publicado: (2012)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
por: Lapa, Constantin, et al.
Publicado: (2018)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Health-related quality of life and clinical outcome after radiotherapy of patients with intracranial meningioma
por: Lisowski, Dominik, et al.
Publicado: (2022)

Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
por: Tamihardja, Jörg, et al.
Publicado: (2022)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

Semi-robotic 6 degree of freedom positioning for intracranial high precision radiotherapy; first phantom and clinical results
por: Wilbert, Jürgen, et al.
Publicado: (2010)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features
por: Zhou, Xiang, et al.
Publicado: (2020)

CXCR4-targeted theranostics in oncology
por: Buck, Andreas K., et al.
Publicado: (2022)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

(68)Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with(18)F-FDG, calcium burden and risk factors
por: Li, Xiang, et al.
Publicado: (2012)

Salvage Nodal Radiotherapy as Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer Detected by Positron Emission Tomography Shows Favorable Outcome in Long-Term Follow-Up
por: Tamihardja, Jörg, et al.
Publicado: (2022)

Novel CYP11B-ligand [(123/131)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
por: Heinze, Britta, et al.
Publicado: (2021)

Radionuclide Imaging of Neurohormonal System of the Heart
por: Chen, Xinyu, et al.
Publicado: (2015)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
por: Habringer, Stefan, et al.
Publicado: (2018)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection
por: Lambertini, Alessandro, et al.
Publicado: (2022)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [(177)Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
por: Hartrampf, Philipp E., et al.
Publicado: (2021)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
por: Kosmala, Aleksander, et al.
Publicado: (2022)

[(18)F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?
por: Kertels, Olivia, et al.
Publicado: (2023)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

Properties of the anisotropy of dose contributions: A planning study on prostate cases
por: Greber, Johannes, et al.
Publicado: (2018)

Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging in Primary Staging of Squamous Cell Carcinoma of the Oral Cavity
por: Linz, Christian, et al.
Publicado: (2021)

Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial
por: Guckenberger, Matthias, et al.
Publicado: (2012)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r92f30vdqujin311j79ld4ak8t